Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : Rhabdomyosarcoma (Low-risk and intermediate-risk)
The standard treatment for Rhabdomyosarcoma is a combination of chemotherapy (treatment with anti-cancer drugs), plus surgery and or radiation therapy (the use of high energy X-rays to kill cancer cells).
One goal of this study is to find the most effective treatment with the least amount of therapy that will still cure participants with low-risk Rhabdomyosarcoma.
There are three parts to this study:
All participants will begin therapy with 4 cycles of chemotherapy. Each cycle will last 3 weeks for a total of 12 weeks. At the end of 12 weeks, you will have scans and tests to recheck your tumor’s response to treatment.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Matthew Krasin, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: email@example.com
For all other inquiries about St. Jude Children's Research Hospital studies: firstname.lastname@example.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.